8-K: CervoMed's Neflamapimod Shows Promise in DLB Trial

CervoMed Inc. announced positive Phase 2b RewinD-LB trial results for neflamapimod, demonstrating significant improvements in neuroinflammation and clinical progression in Dementia with Lewy Bodies patients.

Summary

• CervoMed presented new plasma biomarker data and full clinical results from its Phase 2b RewinD-LB trial for neflamapimod in Dementia with Lewy Bodies (DLB) at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference.
• The initial randomized phase of the trial did not achieve expected plasma drug concentration levels with the neflamapimod capsules used (DP Batch A), which was later attributed to the age of the capsules, resulting in no statistically significant improvement on the primary clinical endpoint or plasma GFAP levels in that phase.
• In the subsequent 32-week open-label extension phase, participants receiving a new batch of capsules (DP Batch B) achieved target plasma concentration levels, leading to significant positive outcomes.
• DP Batch B treatment led to significant reductions in plasma glial fibrillary acidic protein (GFAP), a key marker of neuroinflammation-associated neurodegeneration (median -16.0, IQR: -35, +6.7; p<0.0001 for change from start to Week 32 of the Extension).
• Treatment with DP Batch B also significantly increased the beta amyloid (Ab) 42/40 ratio (p<0.001 compared to start of extension) and showed a trend towards reducing plasma neurofilament light (NfL) chain levels.
• A significant improvement was observed on the primary endpoint, CDR-SB (Clinical Dementia Rating Sum of Boxes), at week 16 of the extension phase, with a mean change that was 52% lower with DP Batch B compared to DP Batch A in all participants and 82% lower in patients with a screening plasma ptau181 of <21.0 pg/mL (i.e., patients without AD co-pathology).
• The clinical effect on CDR-SB was durable to 32 weeks, showing a 65% reduction in clinical worsening in all participants (mean increase=1.73 with DP Batch A vs. 0.53 with DP Batch B) and an 89% reduction in clinical worsening in the <21.0 pg/mL ptau181 subgroup (mean increase=1.44 with DP Batch A vs. 0.16 with DP Batch B).
• Compared to placebo, significant improvement was also seen with DP Batch B on change in CDR-SB (difference= 1.12 point improvement vs. placebo, p=0.005) and the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) (difference= 0.82 point improvement, p=0.004) in within-participant comparisons.
• In the <21.0 pg/mL ptau181 subgroup, DP Batch B reduced the risk of clinical progression (≥1.5 point increase in CDR-SB) by 75% compared to placebo over 16 weeks of treatment, and median time to clinical progression (MTP) increased from 16 weeks for placebo to an estimated 1.5 years with DP Batch B treatment.
• The reduction in plasma GFAP associated with neflamapimod treatment was positively correlated to change in CDR-SB over the 32 weeks of the extension phase (r=.35, p=0.036).
• Neflamapimod was well-tolerated with a low rate of treatment discontinuation over 48 weeks of treatment during the trial. Liver enzyme elevation occurred in 2.5% of neflamapimod recipients in the initial phase and 1.3% in the extension phase, all reversible and not associated with bilirubin elevation.
• The RewinD-LB trial was funded primarily by a $21.3 million grant from the National Institutes of Health's National Institute on Aging.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical and biomarker data for neflamapimod in DLB, particularly after resolving an initial drug bioavailability issue. The results are significant and durable, addressing a high unmet medical need. The planned Phase 3 trial indicates strong confidence, though future funding and regulatory approval remain key risks.

Positives

• Significant reduction in plasma GFAP levels (median -16.0, IQR: -35, +6.7; p<0.0001), a key biomarker of neuroinflammation-associated neurodegeneration.
• Significant increase in Ab42/40 ratio (p<0.001), an inverse marker of neuroinflammation and amyloidogenesis.
• Significant improvement on the primary endpoint, CDR-SB, with a mean change 52% lower with DP Batch B compared to DP Batch A in all participants, and 82% lower in patients without AD co-pathology.
• Durable clinical effect on CDR-SB for 32 weeks, showing a 65% reduction in clinical worsening in all participants and an 89% reduction in the pure DLB subgroup.
• Significant improvement compared to placebo on CDR-SB (1.12 point improvement, p=0.005) and ADCS-CGIC (0.82 point improvement, p=0.004) in within-subject comparisons.
• 75% reduction in the risk of clinical progression (≥1.5 point increase in CDR-SB) in the pure DLB subgroup compared to placebo over 16 weeks.
• Median time to clinical progression increased from 16 weeks for placebo to an estimated 1.5 years with DP Batch B treatment in the pure DLB subgroup.
• Positive correlation between the reduction in plasma GFAP and the slowing of clinical progression (CDR-SB), supporting neflamapimod's mechanism of action.
• Neflamapimod was generally well-tolerated with a low rate of treatment discontinuation over 48 weeks.
• Results reinforce previous Phase 2a study findings and strengthen confidence for an upcoming pivotal Phase 3 trial.

Negatives

• The initial randomized phase of the RewinD-LB trial did not achieve expected plasma drug concentration levels with DP Batch A capsules, which was attributed to the age of the capsules, leading to no statistically significant improvement on the primary clinical endpoint or plasma GFAP levels in that phase.
• Liver enzyme elevation occurred in 2.5% of neflamapimod recipients during the initial phase and 1.3% during the extension phase, although all events were reversible and not associated with bilirubin elevation.

Risks

• The therapeutic potential of neflamapimod, including the degree of sustainability of any therapeutic effects and the meaningfulness of any correlation between any biomarker and clinical effects, may not be replicated in later trials, including the planned Phase 3 clinical trial.
• Uncertainty regarding the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback received from the FDA or other regulatory bodies.
• The Company's need to acquire sufficient funding for any Phase 3 trial of neflamapimod in DLB.
• The Company's available cash resources, the availability of additional funds on acceptable terms, and its ability to continue as a going concern.
• General economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts could impact operations and financial performance.

Future Outlook

CervoMed plans to initiate a global, pivotal Phase 3 trial for neflamapimod in patients with DLB (specifically those without AD co-pathology) in the second half of 2026. The company anticipates potential regulatory submissions and approvals, aiming to address the significant unmet medical need for DLB treatments.

Management Comments

• "The reduction in plasma GFAP levels and the increase in the Ab42/40 ratio, as well as the signal of activity on NfL chain levels indicates to me that neflamapimod broadly improves the neuroinflammatory and neurodegenerative profile in the brain of DLB patients." Charlotte Teunissen, PhD, Professor of Neurochemistry at Amsterdam University Medical Center.
• "The biomarker data presented at CTAD reinforces the results of our previous Phase 2a study and demonstrates a significant correlation between the reduction of plasma GFAP and the slowing of clinical progression in people with DLB. These results highlight the utility of biomarkers such as plasma GFAP and the A42/40 ratio in DLB and suggest that neflamapimod may be acting on the underlying disease process. Together, these findings further strengthen our confidence as we move toward our upcoming Phase 3 trial." Dr. John Alam, Chief Executive Officer of CervoMed.
• "The magnitude of benefit and consistency of data across clinical measures in RewinD-LB provide great confidence that neflamapimod holds true potential to meaningfully slow clinical progression in DLB, a rapidly progressive disease with profound impact on patients and caregivers. Importantly, the results build on a growing body of preclinical and clinical evidence supporting neflamapimods potential and give us renewed confidence that we are moving closer to the first approved treatment for patients and their families." Dr. John-Paul Taylor, MBBS, MRCPsych, PhD, Professor of Translational Dementia Research at Newcastle University and principal investigator of the RewinD-LB trial for the United Kingdom.
• "We're pleased to share for the first time with the academic dementia clinical research community the full results of the RewinD-LB trial. These results include new analyses that demonstrate neflamapimod treatment was associated with significant improvements in both clinical and biomarker measures, including CDR-SB, ADCS-CGIC, and plasma GFAP, in within-participant comparisons to placebo in patients with DLB without AD co-pathology. These findings reinforce our conviction in neflamapimods potential and boost our momentum as we prepare to initiate our pivotal Phase 3 trial next year." Dr. John Alam, Chief Executive Officer of CervoMed.

Industry Context

Dementia with Lewy Bodies (DLB) is the second most common progressive dementia after Alzheimer's disease (AD), affecting millions worldwide. Despite its prevalence and rapid progression, there are currently no approved treatments for DLB in the United States or European Union. Existing standard-of-care therapies only offer temporary symptomatic relief. CervoMed's neflamapimod, by targeting neuroinflammation and synaptic dysfunction, aims to address this significant unmet medical need by potentially slowing disease progression.

Comparison to Industry Standards

• DLB is the second most common progressive dementia after Alzheimer's disease, affecting millions globally.
• There are no approved treatments for DLB in the United States or European Union, indicating a critical unmet medical need.
• DLB typically progresses more rapidly than AD, with patients often requiring nursing home care within two years of diagnosis, underscoring the urgency for effective treatments.
• The observed clinical effects in CervoMed's Phase 2a and Phase 2b trials were most significant in patients with 'pure DLB' (without AD co-pathology), a subgroup representing up to half of the diagnosed patient population, suggesting a targeted efficacy.

Stakeholder Impact

• Shareholders: Positive clinical trial results could lead to increased investor confidence and potential share price appreciation, though future funding needs and regulatory hurdles present ongoing risks.
• Patients with DLB: The promising data offers significant hope for a potential first approved treatment for a rapidly progressive and devastating disease with no current cures.
• Caregivers: A potential treatment that slows disease progression could significantly improve the quality of life for caregivers by extending the time before advanced care is needed.
• Employees: Positive trial results and the progression to a pivotal Phase 3 trial could boost morale and provide greater job security and strategic direction.
• Regulatory Authorities: The robust data will be crucial for future interactions with regulatory bodies like the FDA regarding neflamapimod's approval pathway.

Next Steps

• Initiate a global, pivotal Phase 3 trial for neflamapimod in patients with DLB (specifically those without AD co-pathology) in the second half of 2026.
• Pursue potential regulatory submissions and approvals for neflamapimod for the treatment of DLB.

Key Dates

Recommendation

The positive and durable clinical and biomarker results from the Phase 2b RewinD-LB trial, especially in the pure DLB subgroup, are highly encouraging for a disease with no approved treatments. The significant reduction in clinical worsening and extension of median time to progression demonstrate a meaningful therapeutic effect. While the initial drug batch issue was a setback, its resolution and the subsequent strong data validate the drug's mechanism. The planned pivotal Phase 3 trial in 2026 positions CervoMed for a potential breakthrough in a market with high unmet need. The stock is likely to see significant upside potential given these results, despite the inherent risks of clinical development and future funding requirements.

Keywords

Dementia with Lewy Bodies, DLB, neflamapimod, CervoMed, CRVO, Phase 2b trial, RewinD-LB, neuroinflammation, neurodegeneration, biomarker, GFAP, CDR-SB, clinical trials, biotechnology, neurodegenerative diseases, Alzheimer's Disease, ADCS-CGIC, p38 MAP kinase